General Information
Drug ID
DR00448
Drug Name
Cyclosporine
Synonyms
cyclosporin A; cyclosporine; Ciclosporin; Cyclosporine A; Ciclosporine; Neoral; Cyclosporin; Ciclosporinum; Ciclosporina; Sandimmune; Equoral; Neoplanta; Sandimmun; Sang-35; Gengraf; Sandimmun Neoral; UNII-83HN0GTJ6D; Antibiotic S 7481F1; Consupren; Restasis; Ramihyphin A; SangCyA; MFCD00274558; 83HN0GTJ6D; MLS001333756; CSA; S-Neoral; Cipol N; Sigmasporin Microoral; Sang 35; DSSTox_CID_365; Ciclosporinum [INN-Latin]; Ciclosporine [INN-French]; Ciclosporina [INN-Spanish]; DSSTox_RID_75541; Ciclosporin (Ciclosporin A)
Drug Type
Small molecular drug
Indication Xerophthalmia [ICD11: 5B55.Y] Approved [1]
Therapeutic Class
Immunosuppressive Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5284373"></iframe>
3D MOL 2D MOL
Formula
C62H111N11O12
Canonical SMILES
CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
InChI
InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
InChIKey
PMATZTZNYRCHOR-CGLBZJNRSA-N
CAS Number
CAS 59865-13-3
Pharmaceutical Properties Molecular Weight 1202.6 Topological Polar Surface Area 279
Heavy Atom Count 85 Rotatable Bond Count 15
Hydrogen Bond Donor Count 5 Hydrogen Bond Acceptor Count 12
PubChem CID
5284373
PubChem SID
127280714 , 127280715 , 127280716 , 127280717 , 127280718 , 127280719 , 127280720 , 127280721 , 127280722 , 127280723 , 127280724 , 127280725 , 127280726 , 127280727 , 127280728 , 127280729 , 127280730 , 127280731 , 127280732 , 127300898 , 127300899 , 127300900 , 127300901 , 127300902 , 127300903 , 127300904 , 127300905 , 127300906 , 127300907 , 127300908 , 127300909 , 127300910 , 127300911 , 127300912 , 127300913 , 127300914 , 137018976 , 226407640
ChEBI ID
ChEBI:4031
TTD Drug ID
D0O3YF
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data P-GP Transporter Info Km = 0.17 microM High five cells-MDR1 [5]
P-GP Transporter Info Km = 3.8 microM Human enterocyte-like 2 cells (Caco-2)-MDR1 [6]
P-GP Transporter Info Km = 8.4 microM LLC-PK1 cells-MDR1 [7]
References
1 Cyclosporine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
3 Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol. 2010 Feb;66(2):153-8.
4 Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model. J Pharmacol Exp Ther. 2008 Nov;327(2):592-9.
5 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
6 Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996 Aug;118(7):1841-7. Clinical Trial
7 Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077-80.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.